Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $1.28M fell 5.1% year over year, behind the +9.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 63.9% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.
Context
- Stock-based compensation amounted to 482.6% of revenue in FY2025.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -5.1% toward the trailing-twelve-month pace of +9.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7.46M USD
- Year-over-year change
- +29.2%
- 4-year CAGR
- +0.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.46M | +29.2% |
| FY2024 | 2024-12-31 | 5.78M | -39.4% |
| FY2023 | 2023-12-31 | 9.53M | +5.4% |
| FY2022 | 2022-12-31 | 9.05M | +24.3% |
| FY2021 | 2021-12-31 | 7.28M | — |
Stock-Based Compensation vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.4% is the 3rd highest of 8, against a peer median of -4.1%.
- Stock-based compensation amounts to 344.3% of revenue for MIST, versus a peer median of 210.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding MIST) | — | -4.1% | +3.2% | 210.3% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Depreciation & Amortization | 362K | 89K | 92K | 105K | 114K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.28M | 9.05M | 9.53M | 5.78M | 7.46M |
| Change in Working Capital | 1.62M | (3.26M) | 1.24M | 3.66M | 2.68M |
| Accounts Receivables | 96K | (730K) | (2.64M) | 1.46M | (1.12M) |
| Inventory | 0 | 0 | 0 | 0 | (648K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 4.43M |
| Other Working Capital | 1.52M | (2.53M) | 3.88M | 2.2M | 17K |
| Other Non-Cash Items | 368K | 44K | 2.39M | 3.13M | 3.76M |
| Operating Cash Flow | (33.22M) | (52.47M) | (46.42M) | (28.85M) | (49.04M) |
| Capital Expenditures | 0 | (272K) | (112K) | (33K) | (302K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (15M) | (85.85M) | (137.13M) | (113.55M) | (82.92M) |
| Sales of Investments | 85M | 29M | 142M | 121.87M | 94.47M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 70M | (57.12M) | 4.76M | 8.28M | 11.25M |
| Debt Repayment | 0 | 0 | 50M | 0 | 0 |
| Common Stock Issued | 0 | 2.63M | 0 | 27.26M | 85.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.06M | 458K | (2.21M) | 4.86M | 0 |
| Financing Cash Flow | 5.06M | 3.09M | 47.79M | 32.12M | 85.53M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.83M | (106.51M) | 6.12M | 11.55M | 47.73M |
| Free Cash Flow | (33.22M) | (52.74M) | (46.54M) | (28.88M) | (49.34M) |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.